CompumedicsASX:CMP -7.41%62 EV-to-EBIT is 19.46 as of Jul. 03, 2026, which is 12% below its 10-year median of 22.14. GuruFocus rates ASX:CMP with a GF Score™ of 62/100 and a GF Value™ of A$0.32 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Compumedics ranks worse than 56.65% on this metric.
The historical rank and industry rank for Compumedics's EV-to-EBIT or its related term are showing as below:
ASX:CMP'
s EV-to-EBIT Range Over the Past 10 Years
Min: -14.54 Med: 22.14 Max: 109.73
Current: 19.45
During the past 13 years, the highest EV-to-EBIT of Compumedics was 109.73. The lowest was -14.54. And the median was 22.14.
ASX:CMP's EV-to-EBIT is ranked worse than 56.65% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 18.095
vs ASX:CMP: 19.45
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Compumedics's Enterprise Value for the quarter that ended in Dec. 2025 was A$78.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Compumedics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compumedics EV-to-EBIT Related Terms
Compumedics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Compumedics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Compumedics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Compumedics's EV-to-EBIT falls into.
Compumedics's current Enterprise Value is A$61.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Compumedics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compumedics (ASX:CMP) has a EV-to-EBIT of 19.46 as of Jul. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Compumedics and its competitors. This is 12% below median its historical median of 22.14. According to the industry distribution chart, Compumedics ranks #264 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 56.7%.
Is Compumedics' EV-to-EBIT too high?
Compumedics' current EV-to-EBIT of 19.46 is 12% below median its 10-year median of 22.14. The Medical Devices & Instruments industry median EV-to-EBIT is 18.10. Compumedics' value of 19.46 is 7.5% above this industry median. Based on the distribution chart, Compumedics ranks #264 out of 466 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Compumedics has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #264 out of 466 companies for EV-to-EBIT. This places Compumedics in the lower half of its industry. The industry median EV-to-EBIT is 18.10. Compumedics' value of 19.46 is 7.5% above this benchmark. While the company's 10-year median is 22.14 vs. the industry median of 18.10, Compumedics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.10, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current EV-to-EBIT of 19.46 is 7.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current EV-to-EBIT is 19.46, which is 12% below median its own 10-year median of 22.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.32, compared to a current price of A$0.25 — trading 21.9% below its estimated fair value. The current EV-to-EBIT is 19.46, which is 12% below median its 10-year median of 22.14 and 7.5% above the Medical Devices & Instruments industry median of 18.10. Compumedics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current EV-to-EBIT is 19.46 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.25 is trading 21.9% below its estimated GF Value™ of A$0.32.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
EV-to-EBIT: 19.46 (12% below median its 10-year median of 22.14)
GF Value™: A$0.32 vs. price of A$0.25 (21.9% below fair value)
Industry Position: 7.5% above the Medical Devices & Instruments median (#264 of 466)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
62GF Score
Get the complete analysis for ASX:CMP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
